<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Ovid Therapeutics Inc — News on 6ix</title>
<link>https://6ix.com/company/ovid-therapeutics-inc</link>
<description>Latest news and press releases for Ovid Therapeutics Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Wed, 08 Apr 2026 04:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/ovid-therapeutics-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835a78b78dffbe2df10bff3.webp</url>
<title>Ovid Therapeutics Inc</title>
<link>https://6ix.com/company/ovid-therapeutics-inc</link>
</image>
<item>
<title>Ovid Therapeutics to Host Potassium-Chloride Co-transporter 2 (KCC2) Deep Dive R&D Event on Tuesday, April 14</title>
<link>https://6ix.com/company/ovid-therapeutics-inc/news/ovid-therapeutics-to-host-potassium-chloride-co-transporter-2-kcc2-deep-dive-randd-event-on-tuesday-april-14</link>
<guid isPermaLink="true">https://6ix.com/company/ovid-therapeutics-inc/news/ovid-therapeutics-to-host-potassium-chloride-co-transporter-2-kcc2-deep-dive-randd-event-on-tuesday-april-14</guid>
<pubDate>Wed, 08 Apr 2026 04:00:00 GMT</pubDate>
<description>NEW YORK, April 08, 2026 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company developing small molecule medicines for brain</description>
</item>
<item>
<title>Ovid Therapeutics Announces Pricing of $60 Million Private Placement</title>
<link>https://6ix.com/company/ovid-therapeutics-inc/news/ovid-therapeutics-announces-pricing-of-dollar60-million-private-placement</link>
<guid isPermaLink="true">https://6ix.com/company/ovid-therapeutics-inc/news/ovid-therapeutics-announces-pricing-of-dollar60-million-private-placement</guid>
<pubDate>Wed, 18 Mar 2026 04:00:00 GMT</pubDate>
<description>Proceeds expected to support expansion of next-generation GABA-aminotransferase inhibitor, OV329, into tuberous sclerosis complex and infantile</description>
</item>
<item>
<title>Ovid Therapeutics Announces New OV329 Data and Indication Expansion, Phase 1 Clearance for OV4071, and Reports Fourth Quarter and Full Year 2025 Financial Results</title>
<link>https://6ix.com/company/ovid-therapeutics-inc/news/ovid-therapeutics-announces-new-ov329-data-and-indication-expansion-phase-1-clearance-for-ov4071-and-reports-fourth-quarter-and-full-year-2025-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/ovid-therapeutics-inc/news/ovid-therapeutics-announces-new-ov329-data-and-indication-expansion-phase-1-clearance-for-ov4071-and-reports-fourth-quarter-and-full-year-2025-financial-results</guid>
<pubDate>Wed, 18 Mar 2026 04:00:00 GMT</pubDate>
<description>The 7 mg dose of OV329 demonstrated favorable safety and tolerability profile, reinforcing best-in-category potential for refractory epilepsies; Ovid</description>
</item>
<item>
<title>Ovid Therapeutics to Participate in Upcoming Investor Conferences</title>
<link>https://6ix.com/company/ovid-therapeutics-inc/news/ovid-therapeutics-to-participate-in-upcoming-investor-conferences</link>
<guid isPermaLink="true">https://6ix.com/company/ovid-therapeutics-inc/news/ovid-therapeutics-to-participate-in-upcoming-investor-conferences</guid>
<pubDate>Wed, 25 Feb 2026 05:00:00 GMT</pubDate>
<description>NEW YORK, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company developing small molecule medicines to treat</description>
</item>
<item>
<title>Ovid Therapeutics Reports Phase 1 Results for the First-Ever Direct Activator of Potassium-Chloride Cotransporter 2 (KCC2), OV350 Intravenous (IV)</title>
<link>https://6ix.com/company/ovid-therapeutics-inc/news/ovid-therapeutics-reports-phase-1-130000650</link>
<guid isPermaLink="true">https://6ix.com/company/ovid-therapeutics-inc/news/ovid-therapeutics-reports-phase-1-130000650</guid>
<pubDate>Thu, 18 Dec 2025 13:00:00 GMT</pubDate>
<description>OV350 showed a good safety profile, supporting the advancement of the Company’s KCC2 portfolio, including the first oral direct activator, OV4071There were no treatment-related laboratory findings, no safety findings, and no treatment-related serious adverse events (SAEs)Exploratory quantitative electrophysiology results suggest OV350 had central activity and spectral power consistent with expected physiological effects of KCC2 modulation; aligned with expected drug exposure in the brainPharmaco</description>
</item>
<item>
<title>Ovid Therapeutics Appoints Dr. Petra Kaufmann as Chief Medical Officer</title>
<link>https://6ix.com/company/ovid-therapeutics-inc/news/ovid-therapeutics-appoints-dr-petra-120000328</link>
<guid isPermaLink="true">https://6ix.com/company/ovid-therapeutics-inc/news/ovid-therapeutics-appoints-dr-petra-120000328</guid>
<pubDate>Tue, 02 Dec 2025 12:00:00 GMT</pubDate>
<description>NEW YORK, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company developing small molecule medicines for brain disorders with significant unmet need, today announced the appointment of Petra Kaufmann, M.D., M.S., F.A.A.N., as Chief Medical Officer. Dr. Kaufmann joins Ovid’s leadership team with responsibility for guiding clinical, medical, and regulatory strategy as the Company progresses a clinical pipeline of potential best- and first-in-class ther</description>
</item>
<item>
<title>Ovid Therapeutics Announces Planned Leadership Succession and Reports Business Updates and Third Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/ovid-therapeutics-inc/news/ovid-therapeutics-announces-planned-leadership-120000303</link>
<guid isPermaLink="true">https://6ix.com/company/ovid-therapeutics-inc/news/ovid-therapeutics-announces-planned-leadership-120000303</guid>
<pubDate>Wed, 12 Nov 2025 12:00:00 GMT</pubDate>
<description>Meg Alexander appointed Chief Executive Officer effective January 1, 2026; Dr. Jeremy M. Levin to transition to Executive Chair of the Board of DirectorsNext-generation GABA-aminotransferase (GABA-AT) inhibitor, OV329, demonstrated strong inhibitory activity and a potential best-in-category safety profile in a Phase 1 study, supporting advancement into planned Phase 2 patient studiesOV329 Phase 1 results selected for late-breaking poster presentation at the 2025 American Epilepsy Society (AES) a</description>
</item>
<item>
<title>QurAlis Announces Appointment of Manoj Malhotra, M.D., as Chief Medical Officer</title>
<link>https://6ix.com/company/ovid-therapeutics-inc/news/quralis-announces-appointment-of-manoj-malhotra-md-as-chief-medical-officer</link>
<guid isPermaLink="true">https://6ix.com/company/ovid-therapeutics-inc/news/quralis-announces-appointment-of-manoj-malhotra-md-as-chief-medical-officer</guid>
<pubDate>Mon, 10 Nov 2025 12:45:00 GMT</pubDate>
<description>CAMBRIDGE, Mass., November 10, 2025--QurAlis Corporation, a clinical-stage biotechnology company driving scientific breakthroughs into powerful precision medicines that have the potential to alter the trajectory of neurodegenerative and neurological diseases, today announced that it has appointed Manoj Malhotra, M.D., as chief medical officer (CMO).</description>
</item>
<item>
<title>Ovid Therapeutics Announces Pricing of Private Placement Totaling up to $175 Million in Gross Proceeds</title>
<link>https://6ix.com/company/ovid-therapeutics-inc/news/ovid-therapeutics-announces-pricing-private-110500930</link>
<guid isPermaLink="true">https://6ix.com/company/ovid-therapeutics-inc/news/ovid-therapeutics-announces-pricing-private-110500930</guid>
<pubDate>Fri, 03 Oct 2025 11:05:00 GMT</pubDate>
<description>Initial closing of approximately $81 million expected to fund current operating plan and clinical pipeline into 2028, with potential for up to $94 million in additional proceeds upon exercise of issued warrantsNEW YORK, Oct. 03, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to developing small molecule medicines for brain conditions with significant unmet need, today announced that it has entered into a securities purchase agreement for a p</description>
</item>
<item>
<title>Ovid announces positive topline results for the next-generation GABA-aminotransferase inhibitor, OV329, that demonstrate strong inhibitory activity and a potential best-in-category safety profile</title>
<link>https://6ix.com/company/ovid-therapeutics-inc/news/ovid-announces-positive-topline-results-110000216</link>
<guid isPermaLink="true">https://6ix.com/company/ovid-therapeutics-inc/news/ovid-announces-positive-topline-results-110000216</guid>
<pubDate>Fri, 03 Oct 2025 11:00:00 GMT</pubDate>
<description>An expansive biomarker study confirmed OV329 delivered statistically significant inhibition of GABA-AT as measured across multiple metricsOV329 matched or exceeded inhibition demonstrated by therapeutic doses of first-generation GABA-AT inhibitor, vigabatrin (VGB), as measured on transcranial magnetic stimulation (TMS) 1Findings confirm OV329 penetrates the brain, engages the target and achieves biological modulation as expected of elevated levels of GABA, the major inhibitory neurotransmitterSa</description>
</item>
<item>
<title>Ovid Therapeutics Reports Business Updates and Second Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/ovid-therapeutics-inc/news/ovid-therapeutics-reports-business-updates-120000315</link>
<guid isPermaLink="true">https://6ix.com/company/ovid-therapeutics-inc/news/ovid-therapeutics-reports-business-updates-120000315</guid>
<pubDate>Wed, 13 Aug 2025 12:00:00 GMT</pubDate>
<description>Topline results from the OV329 Phase 1 safety, tolerability and biomarker study remain on track for a readout in Q3 2025$7.0 million royalty monetization agreement signed with Immedica Pharma AB for future ganaxolone royalties, delivering capital to the Company from a non-pipeline assetOV4071, the first ever oral KCC2 direct activator, is completing an IND-enabling package; Ovid anticipates first-in-human studies in Q2 2026Cash, cash equivalents and marketable securities of $38.3 million as of J</description>
</item>
<item>
<title>Ovid Therapeutics to Participate in the BTIG Virtual Biotech Conference</title>
<link>https://6ix.com/company/ovid-therapeutics-inc/news/ovid-therapeutics-participate-btig-virtual-123000402</link>
<guid isPermaLink="true">https://6ix.com/company/ovid-therapeutics-inc/news/ovid-therapeutics-participate-btig-virtual-123000402</guid>
<pubDate>Wed, 23 Jul 2025 12:30:00 GMT</pubDate>
<description>NEW YORK, July 23, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to developing small molecule medicines for brain conditions with significant unmet need, announced today that the Company’s management will participate in the BTIG Virtual Biotechnology Conference being held on July 29-30, 2025. About Ovid TherapeuticsOvid Therapeutics Inc. is a New York-based biopharmaceutical company dedicated to developing small molecule medicines for brain</description>
</item>
<item>
<title>Ovid Therapeutics Enters Agreement with Immedica Pharma AB for Sale of Future Ganaxolone Royalties</title>
<link>https://6ix.com/company/ovid-therapeutics-inc/news/ovid-therapeutics-enters-agreement-immedica-120000634</link>
<guid isPermaLink="true">https://6ix.com/company/ovid-therapeutics-inc/news/ovid-therapeutics-enters-agreement-immedica-120000634</guid>
<pubDate>Wed, 25 Jun 2025 12:00:00 GMT</pubDate>
<description>Non-dilutive funding extends Ovid’s operational runway; Immedica assumes certain ganaxolone IP costsNEW YORK and STOCKHOLM, Sweden, June 25, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to developing small molecule medicines for brain conditions with significant unmet need, today announced that it has entered into a definitive agreement with Immedica Pharma AB (‘Immedica’), a leading global rare disease company, for the sale of its future</description>
</item>
<item>
<title>Ovid Therapeutics to Host Investor and Media Event Thursday, June 12, 2025</title>
<link>https://6ix.com/company/ovid-therapeutics-inc/news/ovid-therapeutics-host-investor-media-113000025</link>
<guid isPermaLink="true">https://6ix.com/company/ovid-therapeutics-inc/news/ovid-therapeutics-host-investor-media-113000025</guid>
<pubDate>Thu, 05 Jun 2025 11:30:00 GMT</pubDate>
<description>Emerging Biomarkers in the Clinical Development of Epilepsy Medicines and OV329 Program HighlightsNEW YORK, June 05, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company dedicated to developing medicines for brain conditions with significant unmet need, will host an investor and media event on Thursday, June 12, 2025, on the topic of applying Biomarkers in Epilepsy, including their strategic use to demonstrate the pharmacodynamic activity of the Company’s O</description>
</item>
<item>
<title>Ovid Therapeutics Reports Business Updates and First Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/ovid-therapeutics-inc/news/ovid-therapeutics-reports-business-updates-120000018</link>
<guid isPermaLink="true">https://6ix.com/company/ovid-therapeutics-inc/news/ovid-therapeutics-reports-business-updates-120000018</guid>
<pubDate>Tue, 13 May 2025 12:00:00 GMT</pubDate>
<description>Topline pharmacodynamic biomarker, safety and tolerability results from a Phase 1 study of OV329 are on track to readout in Q3 2025Ovid’s first program in its KCC2 direct activator library, OV350, has been dosed in a Phase 1 study in Q1 2025; safety and tolerability results expected before year-endCash, cash equivalents and marketable securities of $43.0 million as of March 31, 2025 are expected to support currently planned operations and development programs into the 2H of 2026 NEW YORK, May 13</description>
</item>
<item>
<title>Ovid Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference</title>
<link>https://6ix.com/company/ovid-therapeutics-inc/news/ovid-therapeutics-present-24th-annual-120000041</link>
<guid isPermaLink="true">https://6ix.com/company/ovid-therapeutics-inc/news/ovid-therapeutics-present-24th-annual-120000041</guid>
<pubDate>Wed, 02 Apr 2025 12:00:00 GMT</pubDate>
<description>NEW YORK, April 02, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company dedicated to developing medicines for brain conditions with significant unmet need, today announced that Meg Alexander, President and Chief Operating Officer, will present at the 24th Annual Needham Virtual Healthcare Conference on Monday, April 7, 2025, at 8:45 AM. ET. A live webcast of the Needham Virtual Healthcare Conference presentation can be accessed through the Events & Present</description>
</item>
<item>
<title>Ovid Therapeutics Reports Business Updates and Fourth Quarter and Full Year 2024 Financial Results</title>
<link>https://6ix.com/company/ovid-therapeutics-inc/news/ovid-therapeutics-reports-business-updates-120000702</link>
<guid isPermaLink="true">https://6ix.com/company/ovid-therapeutics-inc/news/ovid-therapeutics-reports-business-updates-120000702</guid>
<pubDate>Tue, 11 Mar 2025 12:00:00 GMT</pubDate>
<description>Stelios Papadopolous, Ph.D., a pioneering leader in biotech, appointed to Board of Directors; two industry veterans joined management team as Ovid prepares to take OV329 into patient trials and move its first KCC2 direct activator into the clinicTopline results from Phase 1 study of OV329 expected in Q3 2025, which will include biomarkers that measure clinical effect and target engagement, safety, and tolerabilityOV350, Ovid’s first program in its KCC2 direct activator library, initiated a first</description>
</item>
<item>
<title>Ovid Therapeutics Appoints Pioneering Industry Leader Dr. Stelios Papadopoulos to Board of Directors</title>
<link>https://6ix.com/company/ovid-therapeutics-inc/news/ovid-therapeutics-appoints-pioneering-industry-130000132</link>
<guid isPermaLink="true">https://6ix.com/company/ovid-therapeutics-inc/news/ovid-therapeutics-appoints-pioneering-industry-130000132</guid>
<pubDate>Mon, 03 Mar 2025 13:00:00 GMT</pubDate>
<description>NEW YORK, March 03, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to developing small-molecule medicines for brain conditions with significant unmet need, today announced the appointment of Stelios Papadopoulos, Ph.D. to its Board of Directors. “Stelios is a pioneering force in biotechnology. His vision and strategic acumen have shaped the landscape of our industry—building companies, financing breakthroughs, and enabling transformative med</description>
</item>
<item>
<title>Ovid Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference</title>
<link>https://6ix.com/company/ovid-therapeutics-inc/news/ovid-therapeutics-present-td-cowen-130000929</link>
<guid isPermaLink="true">https://6ix.com/company/ovid-therapeutics-inc/news/ovid-therapeutics-present-td-cowen-130000929</guid>
<pubDate>Thu, 27 Feb 2025 13:00:00 GMT</pubDate>
<description>NEW YORK, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company dedicated to developing medicines for brain conditions with significant unmet need, today announced that Meg Alexander, President and Chief Operating Officer, will present at the TD Cowen 45th Annual Health Care Conference on Monday, March 3, 2025, at 3:10 p.m. ET in Boston, Massachusetts. A live webcast of the TD Cowen presentation can be accessed through the Events & Presentations sec</description>
</item>
<item>
<title>Ovid Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference</title>
<link>https://6ix.com/company/ovid-therapeutics-inc/news/ovid-therapeutics-to-present-at-the-oppenheimer-35th-annual-healthcare-life-sciences-conference</link>
<guid isPermaLink="true">https://6ix.com/company/ovid-therapeutics-inc/news/ovid-therapeutics-to-present-at-the-oppenheimer-35th-annual-healthcare-life-sciences-conference</guid>
<pubDate>Wed, 05 Feb 2025 05:00:00 GMT</pubDate>
<description>NEW YORK, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to developing medicines for brain</description>
</item>
</channel>
</rss>